{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:26:50Z","timestamp":1790162810203,"version":"4.1.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Benzodiazepines and antipsychotics are frequently prescribed for symptom management in patients with Alzheimer disease and related dementias (ADRD) receiving hospice care, yet evidence guiding their safety and effectiveness is limited.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the association between incident benzodiazepine or antipsychotic use and 180-day mortality among nursing home residents with ADRD enrolled in hospice.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective case-control study used national Medicare claims and Minimum Data Set assessments from July 1, 2014, to September 30, 2018, from US nursing homes providing long-term care. Residents with ADRD newly enrolled in hospice who had no benzodiazepine or antipsychotic use in the prior 6 months were included. Incident users were matched 1:1 to nonusers on enrollment timing, age, sex, comorbidity, cognitive function, and baseline central nervous system medication use. Follow-up was 180 days from hospice enrollment. Analyses were performed from March 2023 to December 2024.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Initiation of benzodiazepine or antipsychotic use during hospice, with no fills of the respective medication class in the prior 6 months.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary outcome was all-cause mortality within 180 days of hospice enrollment. Hazard ratios (HRs) were estimated using Cox proportional hazards regression models adjusting for demographic, clinical, and hospice-level characteristics. Sensitivity analyses included propensity score\u2013weighted models and models accounting for cumulative exposure.<\/jats:p><\/jats:sec>Results<\/jats:title>Among 139 103 participants (105 372 [75.8%] female; mean [SD] age, 87.6 [7.7] years), 26 872 matched pairs were included in the benzodiazepine cohort and 10 240 in the antipsychotic cohort. For the 53 859 participants in matched cohorts, the mean (SD) age was 89.0 (6.4) years, and 45 116 (83.8%) were female. Initiation of benzodiazepine use was associated with higher 180-day mortality compared with nonuse (HR, 1.41; 95% CI, 1.38-1.44), as was initiation of antipsychotic use (HR, 1.16; 95% CI, 1.12-1.20). These findings were consistent across propensity score\u2013weighted models and with greater cumulative exposure.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this national case-control study of nursing home residents with ADRD receiving hospice care, initiation of benzodiazepine or antipsychotic use was associated with increased 180-day mortality. While these medications may provide symptom relief in appropriate clinical scenarios, their use is associated with substantial risks. These findings highlight the need for careful prescribing decisions and the development of dementia-specific hospice prescribing guidelines.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.37551","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:03:11Z","timestamp":1760454191000},"page":"e2537551","source":"Crossref","is-referenced-by-count":9,"title":["Benzodiazepine or Antipsychotic Use and Mortality Risk Among Patients With Dementia in Hospice Care"],"prefix":"10.1001","volume":"8","author":[{"given":"Lauren B.","family":"Gerlach","sequence":"first","affiliation":[{"name":"Department of Psychiatry, University of Michigan Medical School, Ann Arbor"},{"name":"Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Michigan Medical School, Ann Arbor"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyungjin Myra","family":"Kim","sequence":"additional","affiliation":[{"name":"Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor"},{"name":"Consulting for Statistics Computing and Analytics Research, University of Michigan, Ann Arbor"},{"name":"Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Teno","sequence":"additional","affiliation":[{"name":"Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donovan T.","family":"Maust","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of Michigan Medical School, Ann Arbor"},{"name":"Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor"},{"name":"Center for Clinical Management Research, Veterans Affairs Ann Arbor Healthcare System, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"issue":"6","key":"zoi251035r1","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1377\/hlthaff.2021.01985","article-title":"Hospice improves care quality for older adults with dementia in their last month of life.","volume":"41","author":"Harrison","year":"2022","journal-title":"Health Aff (Millwood)"},{"issue":"2","key":"zoi251035r3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1532-5415.2005.53118.x","article-title":"A national study of the location of death for older persons with dementia.","volume":"53","author":"Mitchell","year":"2005","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"zoi251035r4","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1111\/jgs.17066","article-title":"Survival in hospice patients with dementia: the effect of home hospice and nurse visits.","volume":"69","author":"Luth","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"10","key":"zoi251035r5","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1089\/jpm.2013.0595","article-title":"A national study of live discharges from hospice.","volume":"17","author":"Teno","year":"2014","journal-title":"J Palliat Med"},{"issue":"3","key":"zoi251035r6","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1089\/jpm.2021.0055","article-title":"Impact of comorbid dementia on patterns of hospice use.","volume":"25","author":"Aldridge","year":"2022","journal-title":"J Palliat Med"},{"issue":"9","key":"zoi251035r7","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamapsychiatry.2024.1866","article-title":"Hospice enrollment and central nervous system-active medication prescribing to Medicare decedents with dementia.","volume":"81","author":"Gerlach","year":"2024","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"zoi251035r8","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/jgs.17085","article-title":"Prevalence of psychotropic and opioid prescribing among hospice beneficiaries in the United States, 2014-2016.","volume":"69","author":"Gerlach","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"zoi251035r9","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.jamda.2023.04.007","article-title":"Factors associated with benzodiazepine and antipsychotic prescribing in hospice: a qualitative study of hospice prescribers.","volume":"24","author":"Gerlach","year":"2023","journal-title":"J Am Med Dir Assoc"},{"issue":"4","key":"zoi251035r10","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/jgs.15767","article-title":"American Geriatrics Society 2019 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults.","volume":"67","author":"By the 2019 American Geriatrics Society Beers Criteria Update Expert Panel","year":"2019","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"zoi251035r11","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm.","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"zoi251035r12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1176\/appi.ajp.2011.11030347","article-title":"Risk of mortality among individual antipsychotics in patients with dementia.","volume":"169","author":"Kales","year":"2012","journal-title":"Am J Psychiatry"},{"issue":"7","key":"zoi251035r13","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1111\/j.1532-5415.2008.01741.x","article-title":"Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use.","volume":"56","author":"Holmes","year":"2008","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"zoi251035r14","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/archinte.166.6.605","article-title":"Reconsidering medication appropriateness for patients late in life.","volume":"166","author":"Holmes","year":"2006","journal-title":"Arch Intern Med"},{"issue":"4","key":"zoi251035r15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40501-020-00233-9","article-title":"Pharmacological management of neuropsychiatric symptoms of dementia.","volume":"7","author":"Gerlach","year":"2020","journal-title":"Curr Treat Options Psychiatry"},{"issue":"1","key":"zoi251035r16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004770.pub3","article-title":"Drug therapy for delirium in terminally ill adults.","volume":"1","author":"Finucane","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"zoi251035r17","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003945","article-title":"Haloperidol for agitation in dementia.","author":"Lonergan","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"zoi251035r18","article-title":"Haloperidol for the treatment of nausea and vomiting in palliative care patients.","volume":"2015","author":"Murray-Brown","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"zoi251035r19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012555.pub2","article-title":"Olanzapine for the prevention and treatment of cancer-related nausea and vomiting in adults.","volume":"9","author":"Sutherland","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"zoi251035r20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1001\/jamainternmed.2016.7491","article-title":"Efficacy of oral risperidone, haloperidol, or placebo for symptoms of delirium among patients in palliative care: a randomized clinical trial.","volume":"177","author":"Agar","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"6","key":"zoi251035r23","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1093\/gerona\/glab377","article-title":"Identification of dementia in recent Medicare claims data, compared with rigorous clinical assessments.","volume":"77","author":"Grodstein","year":"2022","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"6","key":"zoi251035r24","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1093\/gerona\/glab373","article-title":"Validation of claims algorithms to identify Alzheimer\u2019s disease and related dementias.","volume":"77","author":"McCarthy","year":"2022","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"5","key":"zoi251035r25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1001\/jamainternmed.2024.8579","article-title":"Continued use of cholinesterase inhibitors and memantine in hospice.","volume":"185","author":"Hunt","year":"2025","journal-title":"JAMA Intern Med"},{"issue":"7","key":"zoi251035r26","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores.","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"zoi251035r27","doi-asserted-by":"publisher","first-page":"M546","DOI":"10.1093\/gerona\/54.11.M546","article-title":"Scaling ADLs within the MDS.","volume":"54","author":"Morris","year":"1999","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"9","key":"zoi251035r28","doi-asserted-by":"publisher","first-page":"e68","DOI":"10.1097\/MLR.0000000000000334","article-title":"The Minimum Data Set 3.0 Cognitive Function Scale.","volume":"55","author":"Thomas","year":"2017","journal-title":"Med Care"},{"issue":"3","key":"zoi251035r29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1111\/jgs.16957","article-title":"An MDS 3.0 Distressed Behavior in Dementia Indicator (DBDI): a clinical tool to capture change.","volume":"69","author":"Curyto","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"zoi251035r30","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1111\/jgs.17172","article-title":"Trends in antipsychotic prescribing among long-term care residents receiving hospice care.","volume":"69","author":"Gerlach","year":"2021","journal-title":"J Am Geriatr Soc"},{"issue":"8","key":"zoi251035r31","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1111\/jgs.18344","article-title":"Hospice agency characteristics associated with benzodiazepine and antipsychotic prescribing.","volume":"71","author":"Gerlach","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"15","key":"zoi251035r32","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1007\/s11606-022-07604-3","article-title":"Variation in benzodiazepine and antipsychotic prescribing among hospice agencies.","volume":"37","author":"Gerlach","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"4","key":"zoi251035r33","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1111\/jgs.19320","article-title":"Behavioral symptoms and treatment challenges for patients living with dementia: hospice clinician and caregiver perspectives.","volume":"73","author":"Sadowska","year":"2025","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"zoi251035r34","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1089\/jpm.2015.0376","article-title":"Attitudes toward use of benzodiazepines among U.S. hospice clinicians: survey and review of the literature.","volume":"19","author":"Kamell","year":"2016","journal-title":"J Palliat Med"},{"issue":"5","key":"zoi251035r35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2024.02.059","article-title":"Interventions and predictors of transition to hospice for people living with dementia: a state of the science review.","volume":"67","author":"Gogineni","year":"2024","journal-title":"J Pain Symptom Manage"},{"key":"zoi251035r2","unstructured":"National Alliance for Care at Home. Facts and figures report, 2024 edition. September 10, 2024. Accessed October 1, 2024. https:\/\/allianceforcareathome.org\/resource\/facts-and-figures-report-2024-edition\/"},{"key":"zoi251035r21","unstructured":"Medicare hospice payment reform: analysis of how the Medicare hospice benefit is used. Centers for Medicare & Medicaid Services Chronic Care Policy Group. December 2015. Accessed September 15, 2017. https:\/\/www.cms.gov\/Medicare\/Medicare-Fee-for-Service-Payment\/Hospice\/Downloads\/December-2015-Technical-Report.pdf"},{"key":"zoi251035r22","unstructured":"MDS 3.0 quality measures user manual. Centers for Medicare & Medicaid Services. April 2017. Accessed January 15, 2018. https:\/\/www.cms.gov\/Medicare\/Quality-Initiatives-Patient-Assessment-Instruments\/NursingHomeQualityInits\/Downloads\/MDS-30-QM-Users-Manual-V11-Final.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2840039\/gerlach_2025_oi_251035_1759776624.82784.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:03:15Z","timestamp":1760454195000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2840039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.37551","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]}}}